Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 versus pembrolizumab as first-line treatment for PD-L1-positive advanced non-small cell lung cancer
CTR20222137Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-free survival. Started Nov 2022; status: active.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222137.